S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/BVF Partners/Q4 2025

BVF Partners

Period: Q4 2025 Β· Filed: 2026-02-17
View on SEC EDGAR β†—
AUM
$2.97B
Total portfolio value
Positions
41
Reported securities
Top Holding
KYMR
14.4% $428.2M
QoQ Changes
+2 / -7
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2026-02-17) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
KYMRKYMERA THERAPEUTICS INC$428.2M14.41%$77.81$113.51+45.9%
14.4%
RVMDREVOLUTION MEDICINES INC$267.4M9.00%$79.65$189.24+137.6%
9.0%
MLTXMOONLAKE IMMUNOTHERAPEUTICS$260.3M8.76%$13.18$18.95+43.8%
8.8%
GPCRSTRUCTURE THERAPEUTICS INC$242.0M8.15%$69.55$53.45-23.1%
8.2%
OLMAOLEMA PHARMACEUTICALS INC$132.4M4.46%$25.00$12.64-49.4%
4.5%
MIRMMIRUM PHARMACEUTICALS INC$118.1M3.98%$78.99$125.59+59.0%
4.0%
GHRSGH RESEARCH PLC$112.1M3.77%$12.70$27.01+112.7%
3.8%
XNCRXENCOR INC$109.2M3.68%$15.31$15.00-2.0%
3.7%
ZYMEZYMEWORKS INC$103.7M3.49%$26.33$26.31-0.1%
3.5%
PVLAPALVELLA THERAPEUTICS INC NE$92.0M3.10%$104.67$146.76+40.2%
3.1%
KURAKURA ONCOLOGY INC$89.5M3.01%$10.39$11.10+6.8%
3.0%
STOKSTOKE THERAPEUTICS INC$71.9M2.42%$31.74$32.70+3.0%
2.4%
XOMAXOMA ROYALTY CORPORATION$68.9M2.32%$26.59$43.00+61.7%
2.3%
ABVXABIVAX SA$68.5M2.31%$134.85$144.65+7.3%
2.3%
NKTRNEKTAR THERAPEUTICS$65.9M2.22%$42.28$71.04+68.0%
2.2%
ACIUAC IMMUNE SA$62.2M2.10%$3.14$2.51-20.1%
2.1%
GLUEMONTE ROSA THERAPEUTICS INC$60.1M2.02%$15.68$24.21+54.4%
2.0%
CGEMCULLINAN THERAPEUTICS INC$59.5M2.00%$10.35$17.63+70.3%
2.0%
TYRATYRA BIOSCIENCES INC$55.9M1.88%$26.29$30.62+16.5%
1.9%
IRONDISC MEDICINE INC$51.6M1.74%$79.41$76.26-4.0%
1.7%
IMCRIMMUNOCORE HLDGS PLC$50.3M1.69%$34.71$32.50-6.4%
1.7%
IVVDINVIVYD INC$48.2M1.62%$2.47$0.89-64.0%
1.6%
SEPNSEPTERNA INC$48.0M1.61%$27.88$34.00+21.9%
1.6%
ANNXANNEXON INC$45.8M1.54%$5.02$5.46+8.8%
1.5%
CMPXCOMPASS THERAPEUTICS INC$41.7M1.40%$5.37$2.27-57.7%
1.4%
FDMT4D MOLECULAR THERAPEUTICS IN$34.7M1.17%$7.50$13.00+73.3%
1.2%
CBIOCRESCENT BIOPHARMA INC.$32.6M1.10%$11.86$17.09+44.1%
1.1%
FHTXFOGHORN THERAPEUTICS INC$28.6M0.96%$5.40$5.30-1.9%
1.0%
RPTXREPARE THERAPEUTICS INC$26.9M0.90%β€”β€”
0.9%
AVTXAVALO THERAPEUTICS INC$24.6M0.83%$18.16$18.84+3.7%
0.8%

Quarter-on-Quarter Activity

Q4 2025 vs. Q3 2025

New Positions (2)

TickerIssuerNotionalSince Filing
IRONDISC MEDICINE INC$51.6M-4.0%
IVVDINVIVYD INC$48.2M-64.0%

Exited Positions (7)

TickerIssuerNotional
PTGXPROTAGONIST THERAPEUTICS INC$170.1M
CDTXCIDARA THERAPEUTICS INC$135.4M
CELCCELCUITY INC$32.5M
EPIXESSA PHARMA INC$2.2M
SABSSAB BIOTHERAPEUTICS INC$1.9M
FBRXFORTE BIOSCIENCES INC$1.0M
NLSPNLS PHARMACEUTICS LTD$0.3M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
XNCRXENCOR INC$77.1M+160.3%-2.0%
CBIOCRESCENT BIOPHARMA INC.$16.1M+98.1%+44.1%
CMPXCOMPASS THERAPEUTICS INC$25.1M+63.5%-57.7%
STOKSTOKE THERAPEUTICS INC$33.0M+36.7%+3.0%
ANNXANNEXON INC$24.5M+30.4%+8.8%
NKTRNEKTAR THERAPEUTICS$-6.7M+22.2%+68.0%
GPCRSTRUCTURE THERAPEUTICS INC$152.3M+8.6%-23.1%
AVTXAVALO THERAPEUTICS INC$7.4M+0.0%+3.7%

Trimmed (8)

TickerIssuerNotionalShares Ξ”Since Filing
AXSMAXSOME THERAPEUTICS INC$-50.8M-90.6%
SEPNSEPTERNA INC$-27.6M-57.1%+21.9%
TYRATYRA BIOSCIENCES INC$4.9M-41.7%+16.5%
GLUEMONTE ROSA THERAPEUTICS INC$18.2M-32.2%+54.4%
PVLAPALVELLA THERAPEUTICS INC NE$19.2M-24.3%+40.2%
RVMDREVOLUTION MEDICINES INC$81.7M-15.6%+137.6%
ABVXABIVAX SA$21.1M-9.0%+7.3%
IMCRIMMUNOCORE HLDGS PLC$-6.9M-5.4%-6.4%
← Back to Hedge Funds
BVF Partners Q4 2025 13F Filing β€” Holdings & Portfolio | MarketsFN